Loading, Please Wait...
SAN FRANCISCO, CA--(Marketwired - Mar 16, 2016) - HIV (human immune deficiency virus) is a retrovirus that leads to AIDS (acquired immune deficiency syndrome). It attacks the human immune system and decreases its ability to fight infections. During the last stages of AIDS, the body has no resistance against opportunistic infections and yields to them.
HIV mainly spreads through unprotected sexual contact with an HIV-infected person. Intravenous drug users sharing HIV-infected syringes can also contract this virus. HIV-positive pregnant women may transfer the infection to their children. In addition, transfusion of HIV-infected blood could cause the receiver to contract HIV.
Browse Full Research Report With TOC On "HIV Therapeutics in Major Developed Markets Shares, Strategies, and Forecasts, Worldwide, 2019" at: http://www.radiantinsights.com/research/hiv-therapeutics-in-major-developed-markets-to-2019-limited-pipeline-efficacy-improvement-patent-expirations-and-stringent-healthcare-spending-to-suppress-market-growth
Some signs of HIV infection include tiredness, slight fever, headaches, swollen glands, muscle aches, diarrhea, night sweats, etc. However, these may also occur due to other illnesses, and are not necessarily the symptoms of this infection/illness. In case of doubts, a doctor should be consulted at the earliest for proper guidance.
Wide HIV/AIDS prevalence and research on HIV vaccines propel HIV therapeutics in major developed markets. Novel developments in HIV therapeutics & diagnosis and lower awareness regarding HIV transmission also drive the markets. Affordable & efficient HIV/AIDS treatments and higher awareness of these therapeutics may positively affect these markets.
However, treatment failures, generic drug innovations, and shortage of medical experts can hamper the markets. North America, with Europe following it, is the biggest market. This is credited to the cost-efficiency & availability of HIV/AIDS treatments in the region.
On the contrary, major developed markets are projected to expand sluggishly in the future. Their incomes worth USD 14.3 billion by 2012 should reach nearly USD 16.5 billion by 2019. Key anti-retroviral drugs like Truvada and Atripla will face patent losses in the forecast period.
Browse All Reports Of This Category at: http://www.radiantinsights.com/catalog/pharmaceuticals-and-healthcare
Consequently, HIV therapeutics in major developed markets could witness downwards trends. In spite of these patent losses, multiple drugs may be launched. Among these, 572-Trii would deliver best results (in terms of performance) and also compete with Atripla subsequent to its sanction.
The HIV pipeline is robust, with great diversity & innovations. It caters to the unmet requirements of toxicity & drug resistance. In spite of being promising, the HIV pipeline has encountered huge attrition in the recent past.
Browse Other Upcoming Reports By Radiant Insights, Inc. -
About Radiant Insight
Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets.